- Life sciences company investor Syncona said portfolio company Autolus Therapeutics had dosed the first patient in a trial of a new therapy for treating lymphoma.

The Phase 1/2 LibrA T1 clinical trial was for treatment, AUTO4, which is targeting relapsed or refractory TRBC1-positive peripheral T cell lymphoma.

In addition, Autolus also announced that data on the pre-clinical sister program AUTO5 targeting TRBC2-positive lymphoma were presented at the 60th American Society of Hematology annual meeting in San Diego.

Story provided by